Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncogene suppression by small interfering RNAs.

Olaf Heidenreich1

  • 1Department of Molecular Biology, Institute for Cell Biology, Faculty of Biology, Eberhard-Karls University of Tübingen, 72076 Tübingen, Germany. olaf.heidenreich@uni-tuebingen.de

Current Pharmaceutical Biotechnology
|August 24, 2004
PubMed
Summary

Small interfering RNAs (siRNAs) offer a novel approach to investigate and potentially treat cancers by targeting oncogenes. This method allows for specific cancer therapy with fewer side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same author

Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia.

Haematologica·2026
Same author

B-cell precursor acute lymphoblastic leukaemia with <i>IGH::CEBP</i> rearrangement: what have we learnt over the years?

Haematologica·2026
Same author

Single-cell multiomic atlas of healthy pediatric bone marrow reveals age-dependent differences in lineage differentiation driven by stromal signaling.

Nature immunology·2026
Same author

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Blood·2026
Same author

The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.

Blood·2025

Area of Science:

  • Molecular Biology
  • Oncology
  • RNA Interference Therapeutics

Background:

  • Human cancers accumulate genetic lesions, including oncogene mutations, driving tumor growth.
  • The continuous requirement of specific oncogenes for tumorigenesis is often unclear.
  • Targeting oncogenes with conventional drugs is challenging due to potential side effects on normal cells.

Purpose of the Study:

  • To explore the potential of small interfering RNAs (siRNAs) in analyzing oncogene function in cancer.
  • To discuss the therapeutic promise of oncogene-specific siRNAs for cancer treatment.
  • To review the capabilities and constraints of using siRNAs against oncogenes.

Main Methods:

  • Application of RNA interference (RNAi) principles using small interfering RNAs (siRNAs).

Related Experiment Videos

  • Utilizing mammalian cell culture systems for functional analysis of oncogenes.
  • Reviewing existing literature on siRNA applications in oncogene research.

    • Main Results:

    • RNA interference provides novel tools to study the role of oncogenes in tumor development.
    • Oncogene-specific siRNAs demonstrate potential as targeted cancer therapeutics.
    • Examples of siRNA applications in functional oncogene analysis are presented.

    Conclusions:

    • siRNAs offer a powerful method for both investigating oncogene roles in cancer and developing targeted therapies.
    • Oncogene-targeting siRNAs present a promising avenue for more specific and effective cancer treatment strategies.
    • Further research is needed to fully understand and overcome the limitations of siRNA-based cancer therapies.